ClinicalTrials.Veeva

Menu

Retrospective Study on the Role of SCFA Modulation in Multiple Sclerosis

P

Prof. Massimo Filippi

Status

Active, not recruiting

Conditions

Multiple Sclerosis

Study type

Observational

Funder types

Other

Identifiers

NCT06746896
Brainess FISM

Details and patient eligibility

About

Recent studies show that gut microbiota strongly influences multiple sclerosis. These data suggest that the microbiota could have a direct effect on MS pathogenesis, although the mechanisms through which it modulates central nervous system (CNS) neuroinflammation and neurodegeneration are still poorly defined. The microbiota mediates its action principally through synthesizing specific metabolites that act as messengers in host functions, such as the modulation of the immune and nervous system, tissue repair, and stemness. The short-chain fatty acids (SCFAs- mainly acetate, propionate, and butyrate), produced by the fermentation of dietary fibers, are a class of microbial metabolites of primary importance for host physiology. Thus, the objective is to establish a mechanistic link between gut microbiota dysbiosis, reflected by a different level of SCFAs and SCFA-producing bacteria species, and neuroimmune alterations in MS. Preliminary data show a differential metabolomic profile in urine samples of MS patients compared to healthy controls. The authors now aim at deepening previous findings by analysing also the SCFAs concentration in the urines, plasma and CSF by GC-MS (their level turned out to be too low to be measured by NMR) and the microbiota composition by shotgun metagenomics analysis, to track changes in the abundance of SCFAs-producing bacteria species.

Enrollment

40 patients

Sex

All

Ages

18 to 65 years old

Volunteers

Accepts Healthy Volunteers

Inclusion criteria

  • Volunteers that have preventively signed the informed consent to use their samples for additional studies.

Exclusion criteria

  • None

Trial design

40 participants in 2 patient groups

Healthy Controls
Description:
Absence of neurological symptoms or known diagnosis, absence of a known gastrointestinal pathology.
Newly diagnosed MS patients
Description:
Absence of a known gastrointestinal pathology.

Trial contacts and locations

1

Loading...

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2026 Veeva Systems